1 / 35

Prevention of Chemotherapy-induced Nausea and Vomiting

Prevention of Chemotherapy-induced Nausea and Vomiting. Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV ): Background . Antiemetic Therapy in the Setting of Chemotherapy: The Goal . Impact of CINV on Quality of Life: Complete Control of CINV vs Failure to Control CINV.

talia
Download Presentation

Prevention of Chemotherapy-induced Nausea and Vomiting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prevention of Chemotherapy-induced Nausea and Vomiting

  2. Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV): Background

  3. Antiemetic Therapy in the Setting of Chemotherapy: The Goal

  4. Impact of CINV on Quality of Life:Complete Control of CINV vs Failure to Control CINV

  5. Some of the Pathways Underlying CINV

  6. Some Pathway Triggers Involved in CINV

  7. Clinical Factors Contributing to CINV

  8. Clinician Underestimation of CINV Has Been Demonstrated

  9. CINV: Nuts and Bolts

  10. Not All Chemotherapy is Alike When it Comes to CINV: Emetic Risk of Chemotherapy

  11. Not All Chemotherapy is Alike When it Comes to CINV: Emetic Risk of Chemotherapy (cont)

  12. Importance of Recognizing CINV Risk Factors

  13. The Major Presentations of CINV

  14. Antiemetic Guidelines

  15. Antiemetic Guidelines

  16. Antiemetic Agents in Antiemetic Guidelines

  17. 2013 MASCC/ESMO Antiemetic Guideline Recommendations: Acute Setting

  18. 2013 MASCC/ESMO Antiemetic Guideline Recommendations: Delayed Setting

  19. HEC: Evidence for MASCC/ESMO Recommendation

  20. AC: Evidence for MASCC/ESMO Recommendation

  21. Non-AC MEC: Evidence for MASCC/ESMO Recommendation

  22. 5HT3 RAs: Mechanism of Action

  23. Safety and Antiarrhythmic Issues With Some 5HT3 RAs

  24. Aprepitant or Fosaprepitant: IV or Oral NK1 RA Agent Comparison: Results of a Large Randomized Trial

  25. Minimal Emetic Risk Chemotherapy

  26. Anticipatory CINV

  27. High Level of Agreement Across 3 Major Antiemesis Guidelines: Similarities and Differences

  28. Evidence That Guideline-Based Care is Effective in the Prevention of CINV

  29. Strategies for Monitoring the Effectiveness of Antiemetic Therapy and Enhancing Patient-Clinician Communication About CINV

  30. The MASCC Antiemesis Tool

  31. Challenges and Opportunities in the Prevention of CINV

  32. CINV Prevention: A Brief Look Ahead

  33. Summary

  34. Abbreviations

  35. Abbreviations (cont)

More Related